Ras Al Khaimah, United Arab Emirates -Sunday, August 27th 2017 [ AETOS Wire ] The regional leading pharmaceutical company Julphar announced today that its Board of Directors has appointed Jerome Carle as General Manager – effective immediately. The Board expressed confidence in Jerome’s aptitude and competence to make an immediate impact to the business, to lead the management team and to execute the company’s strategic objectives. The Julphar roadmap – Vision 2020 – will be a key pillar to drive Julphar to the top of the MENA markets. Commenting on his appointment, General Manager Jerome Carle said: “I am very pleased, honored and humbled to have been appointed to this role, and I would like to thank the members of the Board for their trust. I am thrilled to serve a company that makes a real difference in patients and consumers’ quality of life. Julphar is uniquely positioned in the Middle East and African markets to improve the healthcare system and I am proud to play a role in achie ... Read more »

NAIROBI, Kenya -Mardi 29 Août 2017 [ AETOS Wire ] (BUSINESS WIRE) - Aujourd'hui, les grands patrons des industries, les responsables du gouvernement et les PDG des entreprises au Kenya tiendront une réunion pour le prestigieux tournoi de golf annuel du président de l'AIDS Foundation Foundation (AHF) au Kenya au Kiambu Golf Club de Nairobi. Cette année, le tournoi doit accueillir environ 350 personnes, et fournira des informations sur le VIH/SIDA et des services de dépistage du VIH pour pas moins de 150 personnes. Depuis sa création en 2014, le tournoi de golf du président de l'AHF a permis à plus de 1 000 personnes d'accéder aux informations essentielles et aux services de dépistage du VIH/SIDA. Le tournoi vise stratégiquement les grands patrons de la nation, les hauts responsables du gouvernement et les PDG des entreprises qui sont traditionnellement exclus des interventions aux programmes de lutte contre le VIH. Le tournoi de golf du président de l'AHF au Kenya honore l'ambassadeur D ... Read more »

Sensation returns to Dubai for just one night on 10th November and tickets are now on sale Dubai, United Arab Emirates -Wednesday, August 23rd 2017 [ AETOS Wire ] Sensation – returns to the City of Gold on November 10 and tickets are now on sale via platinumlist.net. After three mesmerizing outdoor parties in Dubai, The World’s Leading Dance Event, is proud to announce its much-awaited return with a new show ‘CELEBRATE LIFE’ at Meydan on 10th November 2017. Several ticket types, including hotel packages and Exclusive VIP tables, are on sale now, via platinumlist.net. You can choose to experience Sensation Dubai through a number of ways; all ticket descriptions and prices can be found online. Sensation embarked on three beautiful journeys over the last three years when it all began with a deep experience at the “Source of Light”, then glided into the mesmerizing “Ocean of White” and most recently the experience where imaginations went wild at the “Desert Dome”. This year will be abso ... Read more »

● RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy ● Both Pradaxa® doses tested in RE-DUAL PCI™ have been approved for stroke prevention in atrial fibrillation ● Data were presented as a late-breaker at the ESC Congress 20171 and published in the New England Journal of Medicine2 INGELHEIM, Germany-Sunday, August 27th 2017 [ AETOS Wire ] (BUSINESS WIRE)-- The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) and stent placement: results showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with Pradaxa® when compared to triple therapy with warfarin.1,2 The risk for the primary safety endpoint was 48% lower for Pradaxa® 110 mg dual therapy and 28% lower for Pradaxa® 150 mg ... Read more »

---New Biotechnology Company Accelerates the Delivery of Transformative Innovations in Treatments of Cancer, Inflammatory & Degenerative Diseases, and Functional Regeneration ---Contributions of Capital, More Than 200+ Issued and Pending Patents, Pre-Clinical and Clinical Assets and Commercial Products Obtained from Companies Including Celgene Corporation, Sorrento Therapeutics (Nasdaq: SRNE), United Therapeutics (Nasdaq: UTHR), and Human Longevity, Inc WARREN, N.J.-Wednesday, August 23rd 2017 [ AETOS Wire ] (BUSINESS WIRE)-- Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created th ... Read more »